Modern chemoimmunotherapies have produced higher response rates and improved survival in mantle cell lymphoma (MCL); however, disease relapse remains a challenge. The availability of various post-remission maintenance or consolidation strategies, have led some to question the role of upfront autologous hematopoietic cell transplantation (auto-HCT) consolidation for MCL, in the chemoimmunotherapy-era. A one size fits all approach is no longer appropriate for MCL in first remission, and the choice of preferred post-remission (observation, maintenance or consolidation) strategy is increasingly becoming a factor of patient age, comorbidities and disease risk stratification. In select low-risk patients (based on Mantle cell lymphoma International Prognostic Index (MIPI)), observation following rituximab plus Hyper-CVAD-like inductions seems appropriate. Rituximab maintenance after anthracycline-based chemoimmunotherapies in elderly transplant ineligible patients has shown survival benefit and should be considered a valid option. Limited studies suggest feasibility of radioimmunotherapy consolidation in first remission; however, in the absence of randomized data, this modality remains investigational. In younger, transplant-eligible patients receiving cytarabinecontaining inductions, upfront consolidation with auto-HCT has shown survival benefit, and remains a standard-of-care option in the modern-era. Hyper-CVAD associated stem cell mobilization failure is an increasingly recognized problem, underscoring the need for alternative inductions, or consideration for early stem cell collection, when this induction regimen is used. Outcomes of high-risk MIPI patients remain suboptimal with currently available induction and post-remission strategies and represents an area where adoptive immunotherapy in the form of allogeneic-HCT warrants investigation. Incorporation of novel MoAbs and targeted agents (PI3K inhibitors, mTOR inhibitors, BTK inhibitors and so on.) in maintenance and consolidation strategies will build on the significant therapeutic gains of last decade, in coming years.
INTRODUCTION
Mantle cell lymphoma (MCL) comprises B6% of newly diagnosed non-Hodgkin lymphomas (NHL). 1 The median age at diagnosis is about 68 years with up to 4:1 male predominance. 2 Patients often present with advanced stage disease and extranodal involvement. B symptoms are seen in a third of cases. 3, 4 Over the last decade; strategies including multiagent chemoimmunotherapies either as alone, 5 or as induction followed by high-dose therapy and autologous hematopoietic cell transplantation (auto-HCT) consolidation in first remission, [6] [7] [8] have yielded higher response rates and improved overall outcomes. While these modalities have undoubtedly improved the prognosis of MCL, 9 disease relapse remains problematic. 10, 11 Management of patients with MCL poses a clinical challenge because of the significant biologic heterogeneity of the disease and absence of cure with currently available chemoimmunotherapies. As relapse or progression after initial remission (either CR or PR) is frequent, consideration of consolidation or maintenance strategies remains an active research strategy. There is no consensus, however, about the optimal consolidation or maintenance strategy for MCL patients in first remission.
We review herein the growing and recently published data regarding novel consolidation or maintenance strategies for MCL in remission after frontline therapies, in order to clarify the role and appropriate patient population for upfront HCT in MCL, in the chemoimmunotherapy-era.
SEARCH OF RELEVANT PUBLICATIONS
We searched and identified relevant publications in PubMed and Medline, using the search terms 'mantle cell lymphoma' and 'radioimmunotherapy' or 'maintenance' or 'transplantation' limited to 'English language'. In addition to the online database search, a manual search of the reference lists of reviews and included articles was conducted. Publications that did not include MCL patients were excluded. Also excluded were editorials, letters to the editor, consensus conference papers, practice guidelines and laboratory studies with no clinical correlates. National or international meetings' abstracts (American Society of Hematology, American Society of Blood and Marrow Transplantation, American Society of Clinical Oncology, European Hematology Association, and European Group for Blood and Marrow Transplantation) from January 2009 onwards and www.clinicaltrials.gov were searched to identify ongoing trials evaluating the role of maintenance or consolidation therapies in MCL after first-line therapies. The aim of this review is to critically analyze available (consolidation and/or maintenance) therapy options for MCL patients in first remission after modern chemoimmunotherapies, in order to clarify the role of upfront HCT. Advances in diagnostics, prognostic clinical models, and efficacy of frontline chemoimmunotherapies for MCL have been recently published elsewhere, 12, 13 and is not the main subject of this review. Table 1 describes the criteria used to grade the studies that are included in this review and the criteria to systematically grade the treatment recommendations provided. The quality of published evidence was assessed by analyzing the study design, patient selection criteria, treatment plan (if any) and publication platform (manuscript vs abstract publication). Recommendations in this review article that solely represent the opinion of the authors are clearly indicated.
QUALITATIVE GRADING OF EVIDENCE

RISK STRATIFICATION
The International Prognostic Index (IPI), originally developed for diffuse large B-cell lymphoma (DLBCL), has limited utility in MCL, particularly for the lower risk patients. 13 While histological features (for example, blastoid morphology), 14 tumor proliferation index, 15 gene expression profiling 16 and microRNA expression profile 17 have prognostic value in MCL, their clinical application as a risk stratification tool remains limited. The European MCL Network developed the Mantle cell lymphoma International Prognostic Index (MIPI), as a MCL-specific risk-stratification index. 18 On the basis of the independent prognostic factors included in MIPI (that is, patient age, performance status, lactate dehydrogenase, white blood cell count at diagnosis, ± Ki67 proliferation index), MCL patients are stratified in three groups: MIPI low-risk (median OS not reached), MIPI intermediate-risk (median OS of 51 months) and a MIPI high-risk group (median OS of 29 months). This index has also been validated to predict auto-HCT outcomes. 19 
OBSERVATION AFTER FIRST-LINE CHEMOIMMUNOTHERAPIES
Even though modern chemoimmunotherapies are considered curative for many patients with aggressive NHL (for example, DLBCL and Burkitt lymphoma), 20 this is not the case for the vast majority of MCL cases treated with chemoimmunotherapy alone. In the first prospective report of R-CHOP (rituximab-CY, doxorubicin, VCR, prednisone) in 40 untreated-MCL-patients the median PFS was only 16.6 months, 21 despite a high overall response rate of 96%. In the subsequent comparative German phase III trial, R-CHOP produced higher response rates but displayed no PFS benefit when compared with CHOP alone. Median time-to-treatment failure with R-CHOP was only 12 months. 22 Taken together results from these studies suggest that unlike DLBCL, frontline R-CHOP-like regimens do not appear to provide durable remissions in MCL. This argues for more intensive induction regimens or consideration of continued therapy or intensification (via either maintenance or consolidation strategies) for this particular disease.
Investigators from MD Anderson Cancer Center, employed intensive induction with R-Hyper-CVAD (rituximab, fractionated CY, VCR, doxorubicin, dexamethasone alternating with MTX and cytarabine), without further consolidation therapy in MCL and reported impressive 7 year PFS and OS of 43% and 60%, respectively. 5 However, patients with intermediate/high-risk MIPI or IPI of 3-4 had significantly inferior outcomes (time-to-treatment failure at 8 years was 28% with IPI 3-4 vs 60% for IPI 0-2) in this report, suggesting that intensive induction therapies followed by observation might not be sufficient in higher-risk groups MCL. It is important to point out that these encouraging outcomes with R-Hyper-CVAD were not reproducible in two cooperative group studies, where a significant proportion of patients were unable to complete prescribed therapy due to overwhelming toxicity. 23, 24 The German StiL NHL1 trial has recently demonstrated improved median PFS with bendamustine plus rituximab (BR) over R-CHOP (69.5 vs 31.2 months) in indolent lymphomas including MCL. A subgroup analysis restricted to MCL patients is not yet available to assess the durability of responses following BR. 25 
Recommendations
Observation following intense frontline chemoimmunotherapy with R-Hyper-CVAD appears reasonable in the favorable subgroup of MCL with low MIPI or IPI score (grade B recommendation, level of evidence IIa). Observation alone, however, is not appropriate following R-CHOP-like induction regimens (due to associated relatively short time-to-treatment failure) or in patients with intermediate/high-risk disease. In these situations consolidation or maintenance strategies (as discussed below) should be considered, while balancing risk-benefit considerations such as patient age, comorbidities, and economic impact of such therapies (authors' opinion, grade C recommendation). 
Table1. Levels of evidence and grades of recommendation
Levels of evidence
65
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MAINTENANCE THERAPY FOR MCL IN FIRST REMISSION
The past decade witnessed a remarkable increase in the use of maintenance (immuno)-therapies for management of indolent lymphomas to improve disease control. [26] [27] [28] Various maintenance regimens have been investigated in MCL to prevent relapse after conventional chemo-or chemoimmunotherapies (Table 2) . During the prerituximab-era, the European MCL Network compared auto-HCT consolidation vs IFN-alpha maintenance in MCL achieving a remission after CHOP-like inductions. 2 Despite less hematological toxicity, IFN-alpha maintenance resulted in significantly higher psychomotor and musculoskeletal adverse events and an inferior PFS (25% vs 54%; P-value ¼ 0.01). IFN-alpha maintenance has never been widely used, for these reasons.
Like the majority of B-cell NHLs, bright CD20 expression in MCL renders it an ideal candidate to investigate the role of rituximab for maintenance. The Wisconsin Oncology Network provided preliminary evidence for safety and feasibility of using this approach in MCL. 29 In this pilot study, administration of rituximab monotherapy as maintenance for 2 years after modified R-Hyper-CVAD induction (without MTX/cytarabine-based cycles) provided an encouraging median PFS of 37 months, without any reported grade 4 toxicities during the maintenance period. The role of rituximab maintenance was clearly defined (and perhaps established) in the recently published European MCL Network study, 30 which randomized previously untreated MCL patients to receive either R-CHOP or R-FC (rituximab, fludarabine, CY) induction, followed by a second randomization to receive maintenance with rituximab or IFN-alpha. This landmark study showed significantly longer response duration and an OS advantage with rituximab maintenance. This benefit; however, was limited to those receiving R-CHOP induction ( Table 2 ), suggesting that choice of induction regimen might impact outcomes of subsequent maintenance strategies. Lack of a clear benefit with rituximab maintenance after fludarabine-containing inductions has also been reported with other indolent lymphomas. 26, 31 It is not known whether offering maintenance rituximab would be beneficial after BR induction. An ongoing intergroup trial (E1411) is investigating the role of rituximab maintenance either alone or in combination with lenalidomide in MCL after BR ( ± bortezomib) induction (www.clinicaltrials.gov NCT01415752). Rituximab maintenance in indolent NHL is typically offered for 2-years. The optimal duration of rituximab maintenance in MCL is not clearly defined. The European MCL Network study continued maintenance rituximab until disease progression. Whether maintenance rituximab continued until disease progression is superior to maintenance over a defined period of time (for example, 2-years) warrants investigation.
Bortezomib is approved for relapsed/refractory MCL. 32 Ongoing trials are evaluating the role of maintenance immunotherapies after bortezomib-containing inductions 33 or bortezomib as a maintenance strategy 34 (Table 2) . Dunleavy et al. 34 recently presented in abstract form, results of induction therapy with bortezomib plus DA-EPOCH-R (dose-adjusted etoposide, prednisone, VCR, CY, doxorubicin and rituximab) followed by either bortezomib maintenance or observation. Compared with a historical cohort of patients treated with DA-EPOCH-R alone, patients who received DA-EPOCH-R plus bortezomib had a significantly improved PFS at 48 months (19% vs 50%, respectively).
Recommendations Maintenance using rituximab is reasonable for elderly MCL patients, who are not candidates for HCT, following R-CHOP-like inductions (grade A recommendation, level of evidence Ib). No randomized data are available to support rituximab maintenance after BR or more intensive induction regimens at this time. Similarly, no data are available to suggest superiority (or lack thereof) of maintenance strategies over auto-HCT consolidation in younger patients. Accordingly, maintenance should not be considered an alternative for auto-HCT in transplant-eligible patients (authors' opinion). Bortezomib and lenalidomide maintenance should be considered only within the context of clinical trials (authors' opinion).
RADIOIMMUNOTHERAPY (RIT) CONSOLIDATION FOR MCL IN FIRST REMISSION
RIT delivers radiation to the vicinity of lymphoma in a targeted fashion. Two CD20 Abs conjugated with a radioisotope ( 131 I-tositumomab and 90 Y-ibritumomab tiuxetan) are currently approved for B-cell NHL. 35, 36 Because MCL is radiosensitive and expresses CD20, there is rationale to target radiation directly to MCL cells via CD20. 37 Owing to potentially poor tumor vascular supply following chemotherapy that may limit access of RIT to lymphoma cells, Zelenetz et al. 38 investigated the sequential use of RIT with 131 I-tositumomab followed by CHOP consolidation in newly diagnosed MCL (n ¼ 24). While upfront application of RIT in MCL in this study showed encouraging activity (CR ¼ 46%), which improved to 67% after CHOP consolidation, the median EFS was only 1.4 years. Moreover, patients with persistent minimal residual disease after RIT, had no improvement in minimal residual disease negative rates following CHOP consolidation. 
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The Eastern Cooperative Oncology Group (ECOG) study E1499, evaluated the role of RIT consolidation in untreated MCL patients (n ¼ 56) after four cycles of induction chemoimmunotherapy with R-CHOP. 39 RIT consolidation in this study improved responses (in 22 patients) previously achieved after four cycles of R-CHOP, leading to an overall response rate of 82% (CR ¼ 50%) at completion of therapy. No unexpected toxicities were observed. Median time-to-treatment failure was 34.2 months, comparing favorably with outcomes after R-CHOP induction alone in MCL. 21, 22 Recommendations Consideration of RIT for consolidation in MCL after contemporary chemoimmunotherapy regimens (for example, BR, R-Hyper-CVAD) is feasible (grade B recommendation, level of evidence IIa). No randomized data comparing RIT consolidation vs observation, maintenance and/or auto-HCT are available. In the absence of such data, consideration of RIT should be offered only within the context of a clinical trial (authors' opinion).
AUTOLOGOUS TRANSPLANTATION FOR MCL IN FIRST REMISSION
The grim prognosis of relapsed MCL, with a median survival of 1-2 years, 40 has long been the basis for considering upfront high-dose therapy and auto-HCT consolidation strategies in first remission. The European Group for Blood and Marrow Transplantation and Autologous Bone Marrow Transplant Registry provided preliminary data supporting the role of auto-HCT for MCL after frontline chemotherapies (5 year PFS and OS of 52% and 65%, respectively). 41 These results were subsequently confirmed by the European MCL Network trial (discussed previously), which randomized MCL patients after CHOP-like inductions to either auto-HCT consolidation or IFN-alpha maintenance (Table 3) . 7 Auto-HCT consolidation in this trial was associated with a superior PFS (54% vs 25% at 3 years), but no OS benefit was seen. However, similar randomized trials comparing auto-HCT with non-transplant options in patients treated in the chemoimmunotherapy-era are not available. In the rituximab-era, Vose et al. 42 retrospectively analyzed the outcomes of 58 MCL patients who received auto-HCT in first CR following R-Hyper-CVAD induction from the University of Nebraska Medical Center, and demonstrated a 5-year-OS of 78% compared with 47% for those patients receiving Hyper-CVAD alone (P-value ¼ 0.03).
Several prospective trials have reported favorable outcomes with upfront auto-HCT consolidation in MCL cases receiving rituximab-containing induction regimens 6, 8, 11, [43] [44] [45] [46] (Table 3) . The Cancer and Leukemia Group B 59909 reported encouraging results with upfront auto-HCT in patients receiving MTX plus augmented R-CHOP induction and etoposide/cytarabine/rituximab-based stem cell mobilization (Table 3) . 6 The Nordic Lymphoma Group (MCL-2 trial) 8 also reported impressive results with a MTX-free induction regimen (R maxi-CHOP alternating with R-cytarabine), followed by auto-HCT with in vivo rituximab purged stem cells (6-year-PFS of 66%), with only five relapses seen after long-term follow-up. 11 MCL-2 results compare favorably with the previous Nordic MCL-1 trial (CHOP followed by auto-HCT), where the 4-year-PFS was only 15%. 47 The impressive results of the Cancer and Leukemia Group B 59909 and MCL-2 studies could be attributed to the inclusion of cytarabine as part of intensified induction and perhaps in vivo purging with rituximab during stem cell mobilization. 6, 8 The significance of adding cytarabine to induction regimens was also shown in the recently reported European MCL Network study. 45 This large study randomized patients before auto-HCT to either induction with R-CHOP alone or R-CHOP alternating with R-DHAP (rituximab, DHAP) and demonstrated an OS benefit with cytarabine-containing induction. In MCL patients treated with Hyper-CVAD as frontline therapy, stem cell mobilization failure is increasingly being recognized as a frequent problem. 48, 49 In fact the R-Hyper-CVAD arm of the ongoing US intergroup study (S0016 randomizing MCL patients to R-Hyper-CVAD vs BR followed by auto-HCT) was recently closed due to frequent suboptimal stem cell collections in that arm.
While aforementioned studies establish the efficacy of upfront auto-HCT in MCL with low treatment-related mortality, it is important to acknowledge that they are not a substitute for a Research registry data show that among NHL patients surviving disease-free 2-years post auto-HCT, a baseline diagnosis of MCL was associated with the highest risk of late relapse and treatment failure. 50 MCL patients who are not in CR at the time of upfront autografting fare less well. 19, 44 Unfortunately, preliminary results of Nordic MCL-3 trial investigating the role of adding RIT before autografting to MCL patients not achieving a CR after induction chemoimmunotherapies, did not demonstrate a benefit with this approach. 46 To date, the outcome of the biologically aggressive subgroup characterized by high-risk MIPI have been disappointing with 19, 51 or without 5,52 upfront auto-HCT consolidation, underscoring the need for evaluating novel consolidation modalities for patients.
Recommendations
Acknowledging the lack of randomized data, auto-HCT consolidation for MCL in first remission after cytarabine-containing inductions should be considered a standard option, especially for low-and intermediate-risk MIPI cases (grade A recommendation, level of evidence Ib). Early stem cell collection should be considered when prescribing R-Hyper-CVAD induction (after 3-4 cycles). To improve stem cell collection yield in patients receiving R-Hyper-CVAD therapy, consideration should be given to a chemotherapy-based or plerixafor-based mobilization strategy 53 (grade C recommendation, level of evidence III). Advanced age alone in otherwise healthy individuals, is not considered a contraindication for auto-HCT 54 (grade C recommendation, level of evidence III).
ALLOGENEIC TRANSPLANTATION FOR MCL IN FIRST REMISSION
Adoptive immunotherapy in the form of allo-HCT is frequently considered for patients with relapsed, chemosensitive MCL. 44, 55 No prospective, randomized data assessing the relative risks and benefits of upfront allo-HCT in MCL vs auto-HCT or conventional induction therapies alone are available. MCL refractory to frontline chemoimmunotherapies has extremely poor prognosis, and represents an area where early allo-HCT holds promise as a potentially curative modality. The MD Anderson group reported 6-year-PFS and OS of 46% and 53%, respectively in cohort of 35 mostly relapsed MCL patients. 44 Although this study included seven patients with primary refractory disease, their outcomes were not reported separately. In contrast to patients with primary refractory disease, application of upfront allo-HCT for MCL in first CR or PR is hard to justify. The 3-year-PFS of 57 chemosensitive patients (including 30 patients in first CR/PR) in the British registry Transplantation and beyond in MCL L Chaudhary et al study ranged from 26-31%. 56 Non-randomized registry data from Center for International Blood and Marrow Transplant Research examining the role of allo-HCT vs auto-HCT in MCL patients in first remission (1st CR or PR) showed no benefit in terms of PFS (55% vs 52%) or OS (62% vs 61%), but a significantly higher non-relapse mortality (25% vs 3%) with upfront allografting 57 (Table 4) . These data caution against the routine use of allo-HCT for MCL in first remission. Early allo-HCT may, however, be considered in selected MCL cases with primary refractory disease based on Center for International Blood and Marrow Transplant Research data suggesting that about 20-25% of these cases could be diseasefree 3-years following allografting, despite initial chemorefractory disease. 58 Recommendations Upfront use of allo-HCT in chemosensitive MCL patients in first remission is not recommended. It is not known whether outcomes of high-risk MIPI patients can be improved by early allografting and warrant prospective investigation. Upfront allo-HCT may be considered in patients with primary refractory disease, with good performance status who are not candidates for clinical trials evaluating experimental therapies (authors' opinion and grade C recommendation, level of evidence III). Table 5 summarizes the role of available maintenance and consolidation options for MCL patients who achieve a remission after modern chemoimmunotherapies. This is an exciting time for developmental therapeutics in MCL, with several agents showing promising activity in MCL in clinical trials (for example, ibrutinib [NCT01599949 and NCT01646021], ABT-199 [NCT01594229], obinutuzumab, SAR245409 [NCT01403636]). Moving forward, efforts ought to be focused on evaluating novel consolidation or maintenance strategies, possibly with agents not used in induction chemoimmunotherapies (Table 6 ). Consolidation and/ or maintenance with immunomodulatory agents (for example, lenalidomide; NCT01415752), newer B-cell MoAbs (for example, ofatumumab, MEDI-551, obinutuzumab and so on) or Bruton's tyrosine kinase inhibitors warrant investigation in the post induction and post auto-HCT settings. An ongoing Cancer and Leukemia Group B study is evaluating the role of bortezomib maintenance in MCL after auto-HCT (NCT00310037), while a similar Dutch study has completed accrual and results are awaited (HOVON MCL 75; www.hovon.nl). Routine use of peripheral blood autografts, growth factor administration and modern supportive measures, including more effective antimicrobial agents have undoubtedly improved the safety of auto-HCT and extended its availability to populations previously deemed unsuitable for this procedure. 54, 59, 60 Evaluation of techniques to monitor minimal residual disease post auto-HCT to detect early relapses warrants investigation. minimal residual disease monitoring with PCR (PCR) for Ig heavy chain and/or bcl-1 rearrangement was employed in the MCL-2 trial. 61 In 26 patients experiencing molecular relapse (PCR þ for Ig heavy chain rearrangement) post auto-HCT, preemptive treatment with rituximab achieved a second molecular remission in 92% of the patients. Median molecular and clinical relapse-free survival after pre-emptive treatment were 1.5 and 3.7 years, respectively. In the coming years, novel modalities, namely immuno-transplants (in situ tumor vaccination followed by transplantation of harvested tumor-specific T cells), 62 posttransplant idiotype vaccination, 63 and employing high-dose therapy as a lymphodepleting platform for chimeric Ag receptor T-cell therapy 64 may transform auto-HCT from a 'remission extending' therapy to a potentially curative modality. Clinical trials designed to define optimal consolidation or maintenance strategies based on underlying disease biology (for example, MIPI risk stratification, blastoid histology), rather than dichotomizing the patient population by arbitrary age cutoffs, are needed to improve dismal outcomes of high-risk patients.
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